Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-31
2005-05-31
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S275400, C546S276100
Reexamination Certificate
active
06900230
ABSTRACT:
The present invention relates to compounds of the formulawherein R1, R3, R5, R6, and A are defined as in the specification, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the invention are useful in the treatment of inflammation and other inflammation associated disorders, such as osteoarthritis, rheumatoid arthritis, colon cancer and Alzheimer's disease, in mammals (preferably humans, dogs, cats and livestock).
REFERENCES:
patent: 0418845 (1995-08-01), None
patent: 1099695 (2001-05-01), None
patent: 1104758 (2001-06-01), None
patent: 1104759 (2001-06-01), None
patent: 0554829 (2002-05-01), None
patent: WO 9500501 (1995-01-01), None
patent: WO 9515315 (1995-06-01), None
patent: WO 9515316 (1995-06-01), None
patent: WO 9515317 (1995-06-01), None
patent: WO 9515318 (1995-06-01), None
patent: WO 9603387 (1996-02-01), None
patent: WO 9603392 (1996-02-01), None
patent: WO 9608482 (1996-03-01), None
patent: WO 9619469 (1996-06-01), None
patent: WO 9619864 (1996-06-01), None
patent: WO 9636623 (1996-11-01), None
patent: WO 9711704 (1997-04-01), None
patent: WO 9713755 (1997-04-01), None
patent: WO 9714691 (1997-04-01), None
patent: WO 9716435 (1997-05-01), None
patent: WO 0140216 (2001-06-01), None
Simone, Oncology: Introduction, Cecil Textbook Of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1996.*
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20th Edition, vol. 2, pp. 2050-2057, 1996.*
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20th Edition, vol. 2, pp. 1992-1996, 1996.*
Freston, PubMed Abstract (Am J Med 107(6A):78S-88S; Discussion 89S), Dec. 1999.*
Naesdal et al., PubMed Abstract (Eur J Gastroenterol Hepatol, 13(12):1401-6), Dec. 2001.*
Vane J. R., et al.,Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation, Proc. Natl. Acad. Sci. USA, vo 91, pp. 2046-2050, Mar. 1994.
Penning, T. D., et al.,Synthesis and Biological Evaluation of the 1,5-diarylpyrazole Class of Cyclooxygenas-2 Inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide(SC-58635, Celecoxib), J. Med. Chem., 1997, 40, pp. 1347-1365.
Tsuji, K., et al.,Studies on Anti-inflammatory Agents. IV. Synthesis and Pharmacological Properties of 1,5-Diarylpyrazoles and Related Derivatives, Chem. Pharm. Bull., 45(6), pp. 987-995, 1997.
Rast Bryson
Sakya Subas M.
Hosley Mary J.
Pfizer Inc.
Rao Deepak
Wootton Thomas A.
LandOfFree
Heterocyclo-alkylsulfonyl pyrazoles as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclo-alkylsulfonyl pyrazoles as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclo-alkylsulfonyl pyrazoles as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3454420